Last edition
News about "Mabwell Therapeutics"
Mabwell Presents Clinical Data for Nectin-4 ADC 9MW2821 at ESMO 2026
Clinical studies presented at the 2026 ESMO Gynecological Cancers Congress showed that Mabwell’s Nectin-4-targeting ADC 9MW2821 demonstrated a manageable safety profile, promising efficacy, and notable survival benefits in cervical cancer patients, with encouraging antitumor activity when combined with a PD-1 inhibitor.
Mabwell Therapeutics | 20/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members